We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
3
0 active
Approvals
0
Total approvals
Agencies
Regulatory bodies
Founded
2019
Recruiting
2
66.7%
Withdrawn
1
33.3%
No approval data available
- Astellas Pharma and AviadoBio have entered into an agreement potentially worth $2.2 billion to advance AVB-101, a gene therapy for frontotemporal dementia with progranulin mutations (FTD-GRN). - AVB-101 is currently in Phase I/II development and aims to restore progranulin levels in the brain via a one-time, targeted delivery. - The collaboration includes an upfront payment and equity investment from Astellas, with potential milestone payments and royalties upon exercising the license option. - Frontotemporal dementia is a devastating early-onset dementia with no current cure, highlighting the urgent need for new treatments like AVB-101.
